GENSCRIPT BIO (01548.HK): CARVYKTI Q3 Net Trade Sales About USD 710M
- On 13 October 2026, GENSCRIPT BIO (01548.HK) said associate Legend reported CARVYKTI net trade sales of about USD 710 million for the September 2026 quarter.
- Legend's shares are listed on the Nasdaq Global Select Market in the form of American depositary shares.
NewTimeSpace News: On 13 October 2026, Genscript Biotech Corporation (stock code: 01548.HK) issued a voluntary announcement that Legend Biotech Corporation (Legend), an associate whose shares are listed on the Nasdaq Global Select Market as American depositary shares, filed a Form 6-K with the US Securities and Exchange Commission on 13 October 2026 (New York time, after the Hong Kong trading session). Under the collaboration and licence agreement dated 21 December 2017 between Legend and Janssen Biotech, Inc., CARVYKTI® generated net trade sales of about USD 710 million for the quarter ended 30 September 2026.
The net trade sales were based on information provided by Janssen to Legend, and neither Legend nor the Company independently verified the accuracy of the figure. The Company announced the preliminary sales of CARVYKTI® for the quarters ended 31 March 2026 and 30 June 2026 on 14 April 2026 and 15 July 2026 respectively.
- Implementation of the Pharmaceutical Industry Development “15th Five-Year Plan” and Standout Data for Domestic Novel Drugs at WCLC: Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rose 10.82%
- Going Global Weekly: Mainland Companies Flock to Hong Kong Listings, Pharma Globalisation Shifts to Data and Capability Export-20260918
- GENSCRIPT BIO (01548.HK): Partners with Lilly's TuneLab Platform to Provide Wet-lab Services
- GENSCRIPT BIO (01548.HK) plans to issue in total 77.13 million shares by placement, with estimated net proceeds of HKD 2.33 billion
- GENSCRIPT BIO (01548.HK): Places 77.126 Million New Shares at HKD 30.50 to Raise About HKD 2.327 Billion
